Gujarat Themis Q1 PAT falls over 25% YoY to Rs 13 crore

Last updated: Jul 27, 2024 | 9:51 AM IST

Gujarat Themis Biosyn reported a 25.3% decline in net profit at Rs 13.24 crore in the first quarter of fiscal 2025 as compared to Rs 17.72 crore in the same period last year.

The decline was primarily due to a 21.7% year-on-year decline in net sales at Rs 38.83 crore.

Total operating expenses declined 22.2% to Rs 20.28 crore in the quarter ended June 2024.

As a result, PBIDT declined by 22.4% YoY to Rs 19.07 crore in Q1 FY25 at a margin of 49.11% (as compared to 49.57% in Q1 FY24).

Moreover, during the period under review, the company’s depreciation and amortisation expense increased by 53.3% year-on-year to Rs 1.15 crore.

As a result, profit before tax declined by 25% to Rs 17.86 crore in the first quarter of FY25 as compared to Rs 23.81 crore in the corresponding quarter of the previous year.

Gujarat Themis Biosyn is engaged in the production of active substances namely Rifamycin S and Rifamycin O.

The stock fell 3.91% to close at Rs 483.75 on the BSE on Friday.

Over the past year, Gujarat Themis Biosyn stock has gained 207.26% while the Sensex index has gained 21.92% during the same period.

Powered by Capital Market Live News

Disclaimer: No Business Standard journalist was involved in the creation of this content

First published: Jul 27, 2024 | 9:25 AM IST